通过E-Xanthohumol对SREBP介导的脂质代谢的治疗干扰减弱了前列腺癌的进展

相关实验视频

Updated: Mar 6, 2026

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists

Reverse Yeast Two-hybrid System to Identify Mammalian Nuclear Receptor Residues that Interact with Ligands and/or Antagonists

Published on: November 15, 2013

Jonathan Viehoever¹, Naveen Surya Velmani², Vignesh Basavaraj²

¹International Master's Program of Biomedical Sciences, School of Medicine, China Medical University, Taichung, Taiwan.

Biochemical pharmacology

|March 4, 2026

概括

(E) - 桑托荷摩尔 (EXN) 通过降低SREBP-1/2通路的调节,有效地准前列腺癌 (PCa) 中异常的脂质代谢. 这种天然化合物抑制PCa的生长和进展,为抗割PCa (CRPC) 提供了潜在的新疗法.

科学领域:

生物化学生物化学
在瘤学瘤学.
代谢学代谢学代谢学

背景情况:

由SREBP-1和SREBP-2调节的异常脂质代谢驱动前列腺癌 (PCa) 和耐割PCa (CRPC) 的进展.
针对SREBP通路提供了一种针对PCa中的脂质生成和雄激素受体 (AR) 信号的双重策略.
(E) - 桑托摩尔 (EXN),一种天然的,已知具有代谢调节作用,但其在PCa脂质生成中的作用尚未被探索.

研究的目的:

阐明EXN对PCa细胞失调的脂质代谢作用的分子机制.
在体外和体内确定EXN对PCa侵略性的疗效.
评估EXN作为PCa,特别是CRPC的潜在治疗剂.

主要方法:

在体内对依赖雄激素和CRPCPCa细胞系进行研究,评估生长,迁移,入侵和亡.
西部斑点分析用于评估SREBP-1,SREBP-2,FASN,HMGCR和AR的表达.
脂质组分析以量化甘油三和胆固醇.
使用裸体小鼠异种移植模型进行体内研究,以评估瘤生长衰减.

主要成果:

EXN显著抑制了PCa细胞的生长,迁移和入侵,同时诱导了细胞亡.
在EXN下调了SREBP-1,SREBP-2,FASN,HMGCR和AR的表达.
脂质组分析显示,用EXN治疗的PCa细胞中,甘油三和胆固醇的降低.
在体内,EXN治疗导致CRPC瘤生长的减弱.

结论:

通过准SREBP介导的脂质代谢,EXN显示出显著的抗前列腺癌活性.
EXN有效地抑制PCa细胞的攻击性和CRPC瘤的生长.
EXN代表了PCa的新型治疗候选者,有可能克服当前荷尔蒙疗法的局限性.

关键词:

(E) - - 桑托摩尔 (Xanthohumol) 是一种有毒的物质.脂质新陈代谢脂质新陈代谢利皮多米克 (Lipidomics) 是一种消化剂.前列腺癌治疗疗法前列腺癌治疗

更多相关视频

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

An Orthotopic Murine Model of Human Prostate Cancer Metastasis

Published on: September 18, 2013

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...